Abstracts » Business

When a long shot is worth a shot

Article Abstract:

Northfield Laboratories product, PolyHeme is in phase 3 trials in the United States and Northfield is expected to profit from the product's success though a lot of risk is involved in its manufacturing. Northfield leads the other companies in its business of developing a safe and effective alternative to transfused blood and the positives favoring it include a huge market with no competition on the horizon and a debt-free company with low overhead.

Product development, Biological products industry, Northfield Laboratories Inc., PolyHeme (Medication)

---

The protection racket

Article Abstract:

Some of the ways of insuring against the volatility of the biotech stocks are discussed. It is believed that calls and puts options used as insurance would reduce potential profits by the amount of option premium that is paid for the insurance while on the other hand it also downsizes the risk and will make some profit on the option if losses are incurred.

Management dynamics, Asset & Risk Management, Methods, Management, Risk management, Stock options, Company business management

---

A rollercoaster ride

Article Abstract:

Biotechnology investing has changed in major ways due to the initial public offerings (IPOs) and the reduction in the number of biopharmaceutical approvals. Valuation and speculation are the two major risks for biotech investors.

Forecasts, trends, outlooks, Pharmaceutical preparations, Pharmaceutical industry, Forecasts and trends, Speculation, Market trend/market analysis, Industry forecasts

Some parts © 2012 Advameg, Inc.